In conclusion, our study shows the statistical interrelationships between levels of TIPRL, LC3 and CD133 to HCC/liver cancer aggressiveness, and that prominent diagnostic efficacies of these proteins, either alone or a combination of TIPRL, LC3 and CD133, can be used as biomarkers for early diagnosis of liver cancer. The gene discussed is MAP1LC3A; the disease is hepatocellular carcinoma.